Erratum: Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines (Annals of Oncology (2017) 28 (iv100-iv118) DOI: 10.1093/annonc/mdx216);Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines

Annals of Oncology

Volumn 28, Issue , 2017, Pages iv100-iv118

  Rosello S ^a   Blasco, I ^a   Garca Fabregat L ^a   Cervantes, A ^a   Jordan, K ^b  

^a Centro de Investigación Biomédica en Red de Cáncer   (Spain)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CREMOPHOR; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IPILIMUMAB; OXALIPLATIN; PACLITAXEL; POLYSORBATE 80; RITUXIMAB; TRASTUZUMAB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; DESENSITIZATION; DISEASE SEVERITY; DOCUMENTATION; DRUG EFFICACY; DRUG SAFETY; HOSPITAL ADMISSION; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; PRACTICE GUIDELINE; PREMEDICATION; PRIORITY JOURNAL; RISK ASSESSMENT; ADVERSE DRUG REACTION; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASM; ONCOLOGY; PROCEDURES; STANDARDS;

ANTINEOPLASTIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 85029695024     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy158     Document Type: Erratum

References (91)

1. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13: 725-732
2. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 2010; 14: E10-E21
3. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12: 601-609
4. World Health Organization. International drug monitoring: the role of national centres, report of a WHO meeting [held in Geneva from 20 to 25 September 1971], 1972
5. Commissioner O of the. Reporting Serious Problems to FDA-What is a Serious Adverse Event? [Internet] (09 May 2017, date last accessed). http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm
6. EMA ADR.pdf [Internet]. (09 May 2017, date last accessed). http://www. ema.europa.eu/docs/en_GB/document_library/Regulatory_and_proce dural_guideline/2009/10/WC500004481.pdf
7. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259
8. Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology 2013; 2: e26333
9. Johansson SG, Bieber T, Dahl R et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-836
10. Sampson HA, Munoz-Furlong A, Campbell RL et al. Second symposium on the definition and management of anaphylaxis: summary report-second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006; 47: 373-380
11. Demoly P, Adkinson NF, Brockow K et al. International Consensus on drug allergy. Allergy 2014; 69: 420-437
12. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 2012; 23(Suppl 10): x313-x319
13. Winkler U, Jensen M, Manzke O et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217-2224
14. CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf [Internet]. (09 May 2017, date last accessed) https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4. 03_2010-06-14_QuickReference:5x7.pdf
15. Simons FE, Ardusso LR, Bilò MB et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011; 4: 13-37
16. Cortes J, Moore JO, Maziarz RT et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol 2010; 28: 4207-4213
17. Rituximab.pdf [Internet]. (09 May 2017, date last accessed). http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/000165/WC500025821.pdf
18. Peavy RD, Metcalfe DD. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8: 310-315
19. Gleich GJ, Leiferman KM. Anaphylaxis: implications of monoclonal antibody use in oncology. Oncol (Williston Park) 2009; 23(2 Suppl 1): 7-13
20. Vultaggio A, Castells MC. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin North Am 2014; 34: 615-632
21. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011; 7: 55-63
22. Hecht J. Gastrointestinal toxicity or irinotecan. Oncol (Williston Park) NY 1998; 12(8 Suppl 6): 72-78
23. Ogawa Y, Grant JA. Mediators of anaphylaxis. Immunol Allergy Clin North Am 2007; 27: 249-260
24. Scarlet C. Anaphylaxis. J Infus Nurs [Internet]. (09 May 2017, date last accessed) 2006; 29(1). http://journals.lww.com/journalofinfusionnursing/ Fulltext/2006/01000/Anaphylaxis.8.aspx
25. Lieberman P, Nicklas RA, Oppenheimer J et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126: 477-480
26. Muraro A, Roberts G, Worm M et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014; 69: 1026-1045
27. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013; 28: CD000567
28. Lin RY, Curry A, Pesola GR et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36: 462-468
29. Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005; 22: 272-273
30. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Two case reports. Int Arch Allergy Immunol 2004; 134: 260-261
31. Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med 2011; 183: 847-855
32. Timoney JP, Eagan MM, Sklarin NT. Establishing clinical guidelines for the management of acute hypersensitivity reactions secondary to the administration of chemotherapy/biologic therapy. J Nurs Care Qual [Internet]. (09 May 2017, date last accessed) 2003; 18(1). http://journals. lww.com/jncqjournal/Fulltext/2003/01000/Establishing_Clinical_Guidelines_ for_the.11.aspx
33. Castells MC, Tennant NM, Sloane DE et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122: 574-580
34. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24: 253-262
35. Doxil.pdf [Internet]. (09 May 2017, date last accessed). http://www. accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf
36. Chanan-Khan A, Szebeni J, Savay S et al. Complement activation following first exposure to pegylated liposomal doxorubicin (DoxilVR ): possible role in hypersensitivity reactions. Ann Oncol 2003; 14: 1430-1437
37. Carboplatin.pdf [Internet]. (09 May 2017, date last accessed). http:// www.mhra.gov.uk/home/groups/par/documents/websiteresources/ con2025642.pdf
38. Navo M, Kunthur A, Badell ML et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006; 103: 608-613
39. Markman M, Kennedy A, Webster K et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17: 1141
40. Markman M, Zanotti K, Peterson G et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21: 4611-4614
41. Oxaliplatin.pdf [Internet]. (09 May 2017, date last accessed). http:// www.mhra.gov.uk/home/groups/par/documents/websiteresources/ con041327.pdf
42. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102: 179-187
43. Paclitaxel.pdf [Internet]. (09 May 2017, date last accessed). http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf
44. Price KS, Castells MC. Taxol Reactions. Allergy Asthma Proc 2002, 23: 205-208
45. Yanaranop M, Chaithongwongwatthana S. Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial. Asia Pac J Clin Oncol 2016; 12: 289-99
46. Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-1268
47. Bennett CL, Adegboro OS, Calhoun EA, Raisch D. Beyond the black box: drug-and device-associated hypersensitivity events. Drug Healthc Patient Saf 2010; 2: 1-5
48. Lorenz W, Reimann HJ, Schmal A et al. Histamine release in dogs by Cremophor ELVR and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents Actions 1977; 7: 63-67
49. van Zuylen L, Gianni L, Verweij J et al. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. Anticancer Drugs 2000; 11: 331-337
50. Theis JG, Liau-Chu M, Chan HS et al. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol 1995; 13: 2508-2516
51. Docetaxel.pdf [Internet]. (09 May 2017, date last accessed). http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/000073/WC500035264.pdf
52. Liossis SN, Tsokos GC. Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol 2005; 116: 721-729
53. Cetuximab.pdf [Internet]. (09 May 2017, date last accessed). http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/000558/WC500029119.pdf
54. Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1,3-galactose. N Engl J Med 2008; 358: 1109-1117
55. Siena S, Glynne-Jones R, Adenis A et al. Reduced incidence of infusionrelated reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 2010; 116: 1827-1837
56. Trastuzumab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/000278/WC500074922.pdf
57. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PDL1 immune checkpoint antibodies. Ann Oncol 2015; 26: 2375-2391
58. Gibney GT, Kudchadkar RR, DeConti RC et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015; 21: 712-720
59. Weber JS, Kudchadkar RR, Yu B et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol 2013; 31: 4311-4318
60. Momtaz P, Park V, Panageas KS et al. Safety of infusing ipilimumab over 30 minutes. J Clin Oncol 2015; 33: 3454-3458
61. Chadda S, Larkin M, Jones C et al. The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: A European perspective. J Oncol Pharm Pract 2013; 19: 38-47
62. Brockow K, Schallmayer S, Beyer K et al. Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis. Allergy 2015; 70: 227-35
63. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097
64. Strullu M, Corradini N, Audrain M et al. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Leuk Lymphoma 2010; 51: 1464-1472
65. Bleomycin.pdf [Internet]. (09 May 2017, date last accessed). https:// www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf
66. Etoposide.pdf [Internet]. (09 May 2017, date last accessed). http://www. mhra.gov.uk/home/groups/par/documents/websiteresources/ con102880.pdf
67. Kidera Y, Satoh T, Ueda S, et al. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol 2011; 16: 244-249
68. Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther 1997; 62: 225-229
69. Alemtuzumab.pdf [Internet]. (09 May 2017, date last accessed). http:// ec.europa.eu/health/documents/community-register/2014/20141215130 524/anx_130524_en.pdf
70. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561
71. Atezolizumab.pdf [Internet]. (09 May 2017, date last accessed). https:// www.accessdata.fda.gov/drugsatfda_docs/label/2016/761041lbl.pdf
72. Bevacizumab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/000582/WC500029271.pdf
73. Teachey DT, Lacey SF, Shaw PA et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov [Internet] 2016. (09 May 2017, date last accessed) http://cancerdiscov ery.aacrjournals.org/content/early/2016/04/13/2159-8290.CD-16-0040. abstract
74. Blinatumomab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/003731/WC500198228.pdf
75. Brentuximab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/002455/WC500135055.pdf
76. Timoney J, Chung KY, Park V et al. Cetuximab use without chronic antihistamine premedication. J Clin Oncol 2006; (Suppl): abstr 13521
77. Voorhees PM, Weiss B, Usmani S et al. Management of infusion-related reactions following daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). Blood 2015; 126: 1829
78. Daratumumab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/004077/WC500207296.pdf
79. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17: 6958-6962
80. Ipilimumab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/002213/WC500109299.pdf
81. Sáenz de Santa María García M, Noguerado-Mellado B, Rojas-Pérez-Ezquerra P et al. First case of allergy to nivolumab. J Allergy Clin Immunol Pract [Internet] (09 May 2017, date last accessed) http://www. sciencedirect.com/science/article/pii/S2213219817300272
82. Nivolumab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/003985/WC500189765.pdf
83. Ofatumumab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/001131/WC500093091.pdf
84. Galvao VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract 2015; 3: 175-185
85. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664
86. Panitumumab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/000741/WC500047710.pdf
87. Pembrolizumab.pdf [Internet]. (09 May 2017, date last accessed). http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/003820/WC500190990.pdf
88. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028
89. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
90. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639
91. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144